Helicobacter pylori aggregating activity of gastric mucin with ulcer healing by ebrotidine.
The mucin isolated from gastric secretion of duodenal ulcer patients before and after therapy with a new antiulcer agent, ebrotidine, was assessed for H. pylori aggregating activity and macromolecular organization. Analyses of mucin molecular forms revealed that successful therapy with ebrotidine was accompanied by a 2.6-2.9-fold increase in the high molecular weight mucin form. The H. pylori aggregation inhibition assays showed that therapy with ebrotidine evoked a 4-fold increase in mucin anti-H. pylori titer. The changes in the functional properties of mucin following ebrotidine therapy were also accompanied by a 36% increase in the content of sulfomucin. The results demonstrate that ulcer therapy with ebrotidine lead to a marked enhancement in mucin's qualities associated with maintenance of gastric mucosal integrity and strengthening the indigenous defenses against H. pylori.
Piotrowski
J
J
Research Center, University of Medicine and Dentistry of New Jersey, Newark 07103-2400.
Majka
J
J
Piotrowski
E
E
Murty
V L
VL
Gabryelewicz
A
A
Slomiany
A
A
Slomiany
B L
BL
D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D001557:Benzenesulfonates / Q000494:pharmacology*; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000382:microbiology; D005752:Gastric Mucins / Q000187:drug effects* / Q000378:metabolism; D016480:Helicobacter pylori / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D013844:Thiazoles / Q000494:pharmacology*
D000897:Anti-Ulcer Agents; D001557:Benzenesulfonates; D005752:Gastric Mucins; D013844:Thiazoles; C075156:ebrotidine